Synergistic and Antagonistic Antiproliferative Effects of Ribociclib (Lee011) and Irinotecan (SN38) on Colorectal Cancer Cells

Huang, Chung‐I; Huang, Yi-Kai; Lee, Hui-Ming; Chen, Jian-Han; Su, Yu-Chieh; Lin, Pei

doi:10.21873/anticanres.16353

Cited by 1 publication

(3 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Mitogens, hormones, and growth factors stimulate D-type cyclins to activate CDK4 and CDK6, initiating Rb protein family phosphorylation in the early G1 phase [20,22,23]. This inactivation of Rb leads to E2F transcription factor release, promoting the transcription of E2F response genes for cell cycle progression [3,20,22,24]. Later in the G1 phase, the CDK2/cyclin E complex hyperphosphorylates Rb, crossing the G1/S checkpoint and initiating the S phase.…”

Section: Discussionmentioning

confidence: 99%

“…In the past two decades, CDK4 and CDK6 have emerged as crucial drivers of cell cycle dysregulation in carcinogenesis [3]. The overexpression of CDK4/6 due to genomic alterations is common in most human cancers [21].…”

Section: Discussionmentioning

confidence: 99%

“…Colorectal cancer (CRC), a prevalent digestive system cancer, ranks as the third most common malignant tumor globally, comprising about 10% of all cancers, and is the second leading cause of cancer-related deaths [1,2]. CRC's incidence and mortality rates are on the rise in most countries, especially in the United States, Europe, and Asia [3,4]. Siegel et al estimated that around 153,020 new cases of CRC would be reported in the United States in 2023 [5].…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Involucrasin B Inhibits the Proliferation of Caco-2 Cells by Regulating the TGFβ/SMAD2-3-4 Pathway

Wang,

Lin,

Shi

et al. 2024

Molecules

View full text Add to dashboard Cite

(1) Background: Colorectal cancer (CRC) is the third most common malignant tumor worldwide and the second most common cause of cancer death. However, effective anti-CRC drugs are still lacking in clinical settings. This article investigated the anti-proliferative effect of involucrasin B on CRC Caco-2 cells. (2) Methods: This study employed a sulforhodamine B (SRB) method, colony formation experiments, flow cytometry, FastFUCCI assay, dual luciferase assay, and Western blot analysis for the investigation. (3) Results: The SRB method and colony formation experiments showed that involucrasin B exhibited an inhibitory effect on the Caco-2 cells cultured in vitro. Subsequently, the flow cytometry, FastFUCCI assay, and Western blotting results showed that involucrasin B induced cell cycle arrest in the G1 phase dose-dependently. Involucrasin B significantly enhanced the TGFβ RII protein level and SMAD3 phosphorylation, thus inhibiting the expression of CDK4 and cyclin D1 and causing G1 cell cycle arrest. (4) Conclusion: This study shows that involucrasin B exerts its anti-proliferative effect by regulating the TGFβ/SMAD2-3-4 pathway to cause G1 cycle arrest in Caco-2 cells.

show abstract